For the Inventor, By the Inventor

Enter assignee name

Leiden, Netherlands

Introgene B.v.

USPTO Granted Patents = 18

Trademarks = 1

Forward Citations = 708

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Domenico Valerio (12 out of 21 patents)

Abraham Bout (8 out of 55 patents)

Robert Cornelis Hoeben (6 out of 13 patents)

4. Alex Jan Van Der Eb (4 out of 12 patents)

5. Frits Jacobus Fallaux (4 out of 10 patents)

6. Govert Johan Schouten (3 out of 17 patents)

7. Victor Willem Van Beusechem (3 out of 5 patents)

8. Markus Peter Wilhelmus Einerhand (2 out of 2 patents)

9. Ronald Vogels (1 out of 50 patents)

10. Carl Gustav Figdor (1 out of 15 patents)

11. Stefan Frederik Franciscus Verlinden (1 out of 2 patents)

12. Helmuth Van Es (1 out of 3 patents)

13. Gosse Jan Adema (1 out of 1 patent)

14. Menzo Jans Emco Havenga (1 out of 1 patent)

15. Markus Peter Einerhand (1 out of 2 patents)

18 patents: Sort by Forward Citations

1. 6878549 - Packaging systems for human recombinant adenovirus to be used in gene therapy (2005-04-12),

2. 6602706 - Packaging systems for human recombinant adenovirus to be used in gene therapy (2003-08-05),

3. 6500919 - Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma (2002-12-31),

4. 6498027 - Targeted delivery through a cationic amino acid transporter (2002-12-24),

5. 6472212 - Methods and compositions for genetically modifying primate bone marrow cells (2002-10-29),

6. 6447768 - Methods of gene therapy with a DNA sequence encoding NOS (2002-09-10),

7. 6395519 - Means and methods for nucleic acid delivery vehicle design and nucleic acid transfer (2002-05-28),

8. 6312957 - Genetic modification of primate hemopoietic repopulating stem cells (2001-11-06),

9. 6265212 - Packaging systems for human recombinant adenovirus to be used in gene therapy (2001-07-24),

10. 6261554 - Compositions for targeted gene delivery (2001-07-17),

11. 6238893 - Method for intracellular DNA amplification (2001-05-29),

12. 6232105 - Conditional replication and expression system (2001-05-15),

13. 6204052 - Adenoviral vectors with reduced TNF response and partial E3 region deletion (2001-03-20),

14. 6140103 - Regulated protein expression in stably transfected mammalian cells (2000-10-31),

15. 6051430 - Vectors and methods for providing cells with additional nucleic acid (2000-04-18),

Company Overview

Introgene B.V., based in Leiden, Netherlands, specializes in the development of innovative gene therapy solutions. The company focuses on harnessing advanced genetic engineering techniques to create therapies aimed at treating various genetic disorders and diseases. With a commitment to pioneering research, Introgene is dedicated to advancing the field of gene therapy, contributing to the growing landscape of biopharmaceuticals and personalized medicine. Its work is pivotal in addressing unmet medical needs through cutting-edge technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

18 Patents

#12 in Leiden

#391 in Netherlands

#34,187 in the World

Leiden, Netherlands

Introgene B.v.

Forward Citations = 708

21 inventors:

Domenico Valerio (12 out of 21 patents)

Abraham Bout (8 out of 55 patents)

Robert Cornelis Hoeben (6 out of 13 patents)

4. Alex Jan Van Der Eb (4 out of 12 patents)

5. Frits Jacobus Fallaux (4 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Introgene B.v.. Retrieved from https://idiyas.com/company/introgene-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…